Company profile

Biocad

Biotechnology (biosimilars + biologics)

Privately held: no public share price · Russia

Assets

(9 total)
9Total Assets
2Approved
7Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
BCD-264
Approved
CD38Monoclonal antibody
Multiple Myeloma
netakimab
Approved
IL-17Monoclonal antibody
Psoriatic ArthritisPsoriasis
AcellbiaNo recent activity
Phase 3
CD20Monoclonal antibody
Rheumatoid Arthritis
BCD-132
Phase 3
CD20Monoclonal antibody
Multiple Sclerosis
BCD-248
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
BCD-281
Phase 3
CD20Monoclonal antibody
Multiple Sclerosis
Copaxone-Teva
Phase 3
Mechanism not establishedPeptide
Multiple Sclerosis
Divozilimab
Phase 3
CD20Monoclonal antibody
Systemic Lupus ErythematosusMultiple Sclerosis
Levilimab
Phase 3
IL-6 receptorMonoclonal antibody
Rheumatoid Arthritis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.